Pfizer speeds ahead with bispecific development
The company will imminently start its third pivotal trial of PF-08634404.
Lorikeet fails to fly for MacroGenics
The company ditches lorigerlimab in prostate cancer.
ESMO 2025 – Padcev plus Keytruda sets the perioperative bar
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
Joyo starts its first pivotal trial
While InxMed, Takara and L&L have phase 3 plans in lung cancer and beyond.
Chia Tai keeps the TGF-β faith
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
